Marco Fizzotti

Publications (3)30.48 Total impact

• Article: Complete resolution of life-threatening bleomycin-induced pneumonitis after treatment with imatinib mesylate in a patient with Hodgkin's lymphoma: hope for severe chemotherapy-induced toxicity?

  Fabrizio Carnevale-Schianca, Susanna Gallo, Delia Rota-Scalabrini, Dario Sangiolo, Marco Fizzotti, Daniela Caravelli, Antonio Capaldi, Giancarlo Anselmetti, Erica Palesandro, Lorenzo D'Ambrosio, Valentina Coha, Remo Obert, Massimo Aglietta, Giovanni Grignani
  Journal of Clinical Oncology 06/2011; 29(24):e691-3. · 18.37 Impact Factor
• Article: An acute hepatitis resembling autoimmune hepatitis occurring during imatinib therapy in a gastrointestinal stromal tumor patient.

  Sandra Aliberti, Giovanni Grignani, Paolo Allione, Marco Fizzotti, Giovanni Galatola, Alberto Pisacane, Massimo Aglietta
  American journal of clinical oncology 12/2009; 32(6):640-1. · 2.21 Impact Factor
• Article: Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD.

  Fabrizio Carnevale-Schianca, Alessandro Cignetti, Antonio Capaldi, Katiuscia Vitaggio, Antonella Vallario, Alberto Ricchiardi, Elisa Sperti, Renato Ferraris, Marco Gatti, Giovanni Grignani, [......], Massimo Geuna, Marco Fizzotti, Dario Sangiolo, Antonino Sottile, Giovanni De Rosa, Anna Rosa Bucci, Giorgio Lambertenghi-Deliliers, Edoardo Benedetti, Richard Nash, Massimo Aglietta
  [show abstract] [hide abstract]
  ABSTRACT: A pilot study was conducted to evaluate safety and activity of nonmyeloablative allogeneic hematopoietic cell transplantation (HCT) in colorectal carcinoma (CRC) and to determine whether a T-cell response to a tumor-associated antigen (TAA) was induced. Fifteen patients with metastatic CRC underwent HCT from human leukocyte antigen (HLA)-matched siblings after a nonmyeloablative conditioning regimen. All patients engrafted with a median donor T-cell chimerism of 72% at day +56. Eight patients experienced grades II to IV acute graft-versus-host disease (GVHD). Despite progressive disease before HCT, partial remission and disease stabilization longer than 90 days were observed in 1 and 3 patients, respectively. Induction of TAA-specific T cells was evaluated with a carcinoembryonic antigen (CEA)-specific HLA-A(*)0201 pentamer in 6 patients with CRC. CEA-specific CD8(+) T cells were detected in 3 of 3 patients concomitant with GHVD onset, but not in 3 of 3 patients without GVHD. They were also not detected in 9 of 9 control patients with GVHD who received transplants for diagnoses other than CRC. Antitumor activity of CEA-specific T cells was also validated in vitro. In one patient, the induction of CEA-specific T cells was associated with a decrease of serum CEA levels and a partial response. Thus, graft-versus-host reactions associated with allogeneic HCT can trigger the generation of T cells specific for CEA, and this may be associated with a clinical response.
  Blood 06/2006; 107(9):3795-803. · 9.90 Impact Factor